바이오의약품 수탁제조 시장(2022-2032년) : 원료, 서비스, 제품, 기업 규모, 운영 규모, 지역 및 주요 국가별 시장 분석, 주요 기업, COVID-19 회복 예측

Biopharmaceuticals Contract Manufacturing Market Report 2022-2032: Forecasts by Source, by Service, by Product, by Company Size, by Scale of Operations, Regional & Leading National Market Analysis, Leading Companies, and COVID-19 Recovery

￡ 3,999 ￦ 6,323,000

Unprintable PDF (Single User) - 1 Year License

1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.

￡ 4,500 ￦ 7,116,000

PDF (Team License - Up to 6 Users) - 1 Year License

￡ 5,500 ￦ 8,697,000

PDF (Site License)

동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

￡ 6,999 ￦ 11,067,000

PDF (Enterprise License - Includes Free Datasets)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.

한글목차

미국은 바이오의약품 비지니스에서 세계를 선도하고 있으며, 세계의 '생명과학 혁신 캐피탈'로 불리며 바이오의약품의 중요한 투자국이 되고 있습니다. 바이오의약품의 수요 증가는 미국 바이오의약품 업계의 확대를 지원하는 것으로 생각되고 있습니다.

또한 COVID-19 팬데믹에 의해 인도의 바이오의약품 부문이 각광을 받고 있습니다. 인도의 바이오테크놀러지 산업은 새로운 성장 단계를 맞이하고 있으며, 사람들의 생활에 접하여 개선하기 위한 큰 가능성을 내포한 산업으로서 세계 각국으로부터 높은 평가를 받고 있습니다.

세계의 바이오의약품 수탁제조 시장에 대해 조사했으며, 시장 규모 및 예측, 시장 역학, 부문·지역별 시장 분석, 시장 점유율, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

샘플 뷰

목차

제1장 리포트의 개요

제2장 개요

• 지역 분석(2022)
• 시장 기회
• 바이오의약품에서 새로운 아웃소싱의 동향
• 수탁제조업에 매출 기회를 생성하는 RNA 기반 COVID-19 백신의 수요
• 연구개발에 대한 투자의 증가
• 애널리스트의 견해

제3장 시장 역학

• 촉진요인
  • 생산능력 확대를 위한 CMO에 의한 투자의 증가
  • 계약 서비스에 의해 제공되는 비용과 시간 절약의 이점
  • 아웃소싱
  • 희귀의약품에 대한 투자 확대
• 억제요인
  • 가격 압력
  • 규제 시나리오
  • 과잉인 생산
• 시장 기회
  • Fill-and-Finish CMO의 확장
  • 일회용 바이오프로세싱 기기 및 솔루션의 출현
  • 유리한 성장 기회를 제공하는 신흥 경제국
• COVID-19가 시장에 미치는 영향
• SWOT 분석
• Porter의 산업 분석
• PEST 분석

제4장 원료별 : 바이오의약품 수탁제조 시장

• 포유류
• 비포유류

제5장 서비스별 : 바이오의약품 수탁제조 시장

• 프로세스 개발 부문
• 충전 및 가공 작업 부문
• 분석 및 QC 연구 부문
• 포장 부문

제6장 제품별 : 바이오의약품 수탁제조 시장

• 생물제제 부문
• 바이오시밀러 부문

제7장 기업 규모별 : 바이오의약품 수탁제조 시장

• 소규모 부문
• 중규모 부문
• 대규모 부문

제8장 운영 규모별 : 바이오의약품 수탁제조 시장

• 전임상 부문
• 임상 부문
• 상업 부문

제9장 지역 및 주요 국가의 바이오의약품 수탁제조 시장 예측(2022-2032)

• 세계의 바이오의약품 수탁제조 시장
• COVID-19 영향 회복 시나리오(V, U, W, L)

제10장 북미의 바이오의약품 수탁제조 시장

• 지역의 개요
• 국가별
• 원료별
• 서비스별
• 제품별
• 기업 규모별
• 운영 규모별
• 미국
• 캐나다

제11장 유럽의 바이오의약품 수탁제조 시장

• 지역의 개요
• 국가별
• 원료별
• 서비스별
• 제품별
• 기업 규모별
• 운영 규모별
• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 기타

제12장 아시아태평양의 바이오의약품 수탁제조 시장

• 지역의 개요
• 국가별
• 원료별
• 서비스별
• 제품별
• 기업 규모별
• 운영 규모별
• 일본
• 중국
• 인도
• 호주
• 동남아시아
• 기타

제13장 라틴아메리카의 바이오의약품 수탁제조 시장

• 지역의 개요
• 국가별
• 원료별
• 서비스별
• 제품별
• 기업 규모별
• 운영 규모별
• 브라질
• 멕시코
• 아르헨티나
• 기타

제14장 중동·아프리카의 바이오의약품 수탁제조 시장

• 지역의 개요
• 국가별
• 원료별
• 서비스별
• 제품별
• 기업 규모별
• 운영 규모별
• GCC
• 남아프리카공화국
• 기타

제15장 기업 개요

• AbbVie, Inc.
• AGC Biologics
• Avantor
• Binex Co., Ltd.
• Boehringer Ingelheim GmbH
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Lonza
• ProBioGen
• Rentschler Biopharma SE
• Samsung BioLogics
• Sandoz
• TOYOBO CO., LTD.
• WuXi Biologics
• JRS PHARMA
• Thermo Fisher Scientific
• Cambrex Corporation
• Curia Global, Inc.
• Pfizer CentreOne
• Jubilant Pharma Limited

제16장 결론과 제안

KSA 22.04.06

영문 목차

영문목차

Title:
Biopharmaceuticals Contract Manufacturing Market Report 2022-2032
Forecasts by Source (Mammalian, Non-mammalian), by Service (Process Development (Downstream, Upstream), Fill & Finish Operations, Analytical & QC Studies, Packaging), by Product (Biologics (Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others), Biosimilars), by Company Size (Small, Mid-sized, Large), by Scale of Operations (Preclinical, Clinical, Commercial) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.

Biopharmaceuticals Contract Manufacturing Market, 2022 to 2032- our new study reveals the latest industry trends, R&D progress, and predicted revenues

The U.S. is the Global Leader in Biopharmaceutical Business

The United States has been dubbed the "life sciences innovation capital" of the world, and it is a significant biopharmaceutical investor. The increased demand for biologics is likely to boost the expansion of the US biopharmaceuticals industry.

In terms of economic contributions and overall impacts, the biopharmaceutical sector in the United States is not only a worldwide leader in the development of innovative medicines, vaccines, and diagnostics, but it is also a highly valued industry. With a diverse employment base and vast research, manufacturing, and distribution infrastructure, the biopharmaceutical business in the United States is a major and innovative component of the country's economy, with considerable influence on economies around the country.

There is a vast innovation ecosystem in the biopharmaceutical industry that drives and maintains this success. An extensive network of collaborators supports the discovery, development, and delivery of new medicines to patients through this innovation ecosystem, which is led by both small and large R&D-intensive companies. This network includes but is not limited to venture and other forms of private capital; health care providers; public and private sector researchers including academic medical researchers and private research institutes; and various other sectors. A strong biopharmaceutical innovation ecosystem and innovation-based policy make the United States the world leader in biopharmaceutical innovation. All these factors are anticipated to fuel the biopharmaceutical contract manufacturing market in the United States.

COVID-19 pandemic has brought India's Biopharmaceuticals Sector into the Limelight

The Indian biotechnology industry has entered a new phase of growth, with the rest of the world increasingly appreciating the sector's enormous potential to touch and improve people's lives. In the middle of the pandemic, the successful production of contingent commodities like the Covid-19 vaccine and indigenous diagnostic kits in such a brief period has been a wonderful benefit to humanity. The Biotechnology Industry Research and Development Corporation (BIRAC) and the Department of Biotechnology (DBT) have been at the forefront of enhancing the country's creative talents and potential.

The development of alternative Covid 19 solutions has been hastened by the Government of India's Mission program COVID Suraksha and the Covid-19 Research Consortium, which is led by DBT and BIRAC. With significant contributions from different states, the nation is on its way to becoming a globally renowned Innovation Hub and Biomanufacturing Hub. Official Biotech policies are in existence or being developed in several states. It is the responsibility of the Department of Biotechnology's Make In India (MII) Facilitation Cell, based at BIRAC alongside Invest India, to interact with States and assist them in formulating biotech policies, promote direct foreign investment, and improve the manufacturing sector, among other things.

What are the Market Driversw

• Rise in Investment by CMOs for Capacity Expansion

• Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals

• Notable growth of biologics

• Robust biopharmaceuticals pipeline

• Cost and time-saving benefits offered by contract services

• Outsourcing as a Driver for Market Growth

• Growing Investments in Orphan Drugs

What are the Market Opportunities?

• Expansion of Fill and Finish CMOs
• Funding & investments
• Emerging Economies to Offer Lucrative Growth Opportunities
• Emergence of Single-Use Bioprocessing Equipment & Solutions

Discover how to stay ahead

Our 650+ page report provides 700+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at the overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biopharmaceuticals Contract Manufacturing Market. See how to exploit the opportunities.

Forecasts to 2032 and other analyses reveal the commercial prospects

• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.

• You find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter's Five Forces, SWOT Analysis, product profiles, and commercial developments.

Discover sales predictions for the world market and sub-markets

Source

• Mammalian
• Non-mammalian

Service

• Process Development
  • Downstream
  • Upstream

• Fill & Finish Operations
• Analytical & QC studies
• Packaging

Product

• Biologics
  • Monoclonal antibodies (MABs)
  • Recombinant Proteins
  • Vaccines
  • Others

• Biosimilars

Company Size

• Small
• Mid-sized
• Large

Scale of Operations

• Preclinical
• Clinical
• Commercial

Region

• North America
• Europe
• Asia Pacific
• Latin America
• MEA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 17 leading national markets:

By Region

• North America
  • U.S.
  • Canada

• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific

• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Leading companies and the potential for market growth

Overall world revenue for Biopharmaceuticals Contract Manufacturing Market will surpass US$xx billion in 2022, our work calculates. We predict strong revenue growth through 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biopharmaceuticals Contract Manufacturing Market report helps you

In summary, our 650+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Biopharmaceuticals Contract Manufacturing Market, with forecasts for 5 segmentations of the biopharmaceuticals contract manufacturing market, with forecasts for 2 Sources, 4 Services, 2 Products, 2 Company Size, and 3 Scale of Operations sub-segments each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2032 for 5 regional and 17 key national markets- See forecasts for the Biopharmaceuticals Contract Manufacturing market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, among other prominent economies.

• Prospects for established firms and those seeking to enter the market- including company profiles for 18 of the companies involved in the Biopharmaceuticals Contract Manufacturing Market. Some of the companies profiled in this report include: AbbVie, Inc., AGC Biologics, Avantor, Binex Co., Ltd., Boehringer Ingelheim GmbH, Cambrex Corporation, Curia Global, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., JRS PHARMA, Jubilant Pharma Limited, Lonza, Pfizer CentreOne, ProBioGen, Rentschler Biopharma SE, Samsung Biologics, Sandoz, TOYOBO CO., LTD., Thermo Fisher Scientific, and WuXi Biologics, among other prominent players.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Biopharmaceuticals Contract Manufacturing Market and leading companies. You will find data, trends, and predictions.

Table of Contents

1. Report Overview

• 1.1 Introduction to Biopharmaceuticals Contract Manufacturing Market
• 1.2 Biopharmaceuticals Contract Manufacturing Market Definition
• 1.3 Why You Should Read This Report
• 1.4 What This Report Delivers
• 1.5 Key Questions Answered By This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 COVID-19 Impact: Recovery Scenarios
  • 1.7.2 Market Evaluation & Forecasting Methodology
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

• 2.1 Regional Analysis, 2022
• 2.2 Opportunities
• 2.3 Emerging Outsourcing Trends in Biopharmaceuticals
• 2.4 Demand for RNA-based COVID-19 Vaccines Creates Revenue Opportunities for Contact Manufacturers
• 2.5 Increase in Investment in Research & Development
• 2.6 Analyst Viewpoint

3 Market Dynamics

• 3.1 Drivers
  • 3.1.1 Rise in Investment by CMOs for Capacity Expansion
  • 3.1.2 Cost and Time Saving Benefits Offered by Contract Services
  • 3.1.3 Outsourcing as a Driver for Market Growth
  • 3.1.4 Growing Investments in Orphan Drugs
• 3.2 Restraints
  • 3.2.1 Pricing Pressure to Impede Market Growth Through 2031
  • 3.2.2 Regulatory Scenarios to Restrain Market Growth
  • 3.2.3 Excessive Production is Projected to Impede Market Growth
• 3.3 Opportunities
  • 3.3.1 Expansion of Fill-and-Finish CMOs
  • 3.3.2 Emergence of Single-Use Bioprocessing Equipment & Solutions
  • 3.3.3 Emerging Economies to Offer Lucrative Growth Opportunities
• 3.4 Impact of COVID-19 on Biopharmaceutical Contract Manufacturing Market
• 3.5 SWOT Analysis
  • 3.5.1 Strengths
  • 3.5.2 Weaknesses
  • 3.5.3 Opportunities
  • 3.5.4 Threats
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Buyer Power of Suppliers (Low)
  • 3.6.2 Supplier Power (Medium)
  • 3.6.3 Competitive Rivalry (High)
  • 3.6.4 Threat of Substitute (Medium)
  • 3.6.5 Threat of New Entrants (Low)
• 3.7 PEST Analysis
  • 3.7.1 Political Factors Impacting Biopharmaceuticals Contract Manufacturing Market
  • 3.7.2 Economic Factors Impacting Biopharmaceuticals Contract Manufacturing Market
  • 3.7.3 Social Factors Impacting Biopharmaceuticals Contract Manufacturing Market
  • 3.7.4 Technological Factors Impacting Biopharmaceuticals Contract Manufacturing Market

4 Biopharmaceuticals Contract Manufacturing Market by Source

• 4.1 Mammalian Segment Market Forecast, 2022-2032
  • 4.1.1 Segment Overview
  • 4.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 4.2 Non-mammalian Segment Market Forecast, 2022-2032
  • 4.2.1 Segment Overview
  • 4.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)

5 Biopharmaceuticals Contract Manufacturing Market by Service

• 5.1 Process Development Segment Market Forecast, 2022-2032
  • 5.1.1 Upstream Process Development
  • 5.1.2 Downstream Process Development
  • 5.1.3 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 5.2 Fill & Finish Operations Segment Market Forecast, 2022-2032
  • 5.2.1 Segment Overview
  • 5.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 5.3 Analytical & QC Studies Segment Market Forecast, 2022-2032
  • 5.3.1 Segment Overview
  • 5.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 5.4 Packaging Segment Market Forecast, 2022-2032
  • 5.4.1 Segment Overview
  • 5.4.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)

6 Biopharmaceuticals Contract Manufacturing Market by Product

• 6.1 Biologics Segment Market Forecast, 2022-2032
  • 6.1.1 Segment Overview
  • 6.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 6.2 Biosimilars Segment Market Forecast, 2022-2032
  • 6.2.1 Segment Overview
  • 6.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)

7 Biopharmaceuticals Contract Manufacturing Market by Company Size

• 7.1 Small Segment Market Forecast, 2022-2032
  • 7.1.1 Segment Overview
  • 7.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 7.2 Mid-sized Segment Market Forecast, 2022-2032
  • 7.2.1 Segment Overview
  • 7.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 7.3 Large Segment Market Forecast, 2022-2032
  • 7.3.1 Segment Overview
  • 7.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)

8 Biopharmaceuticals Contract Manufacturing Market by Scale of Operations

• 8.1 Preclinical Segment Market Forecast, 2022-2032
  • 8.1.1 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 8.2 Clinical Segment Market Forecast, 2022-2032
  • 8.2.1 Segment Overview
  • 8.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
• 8.3 Commercial Segment Market Forecast, 2022-2032
  • 8.3.1 Segment Overview
  • 8.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)

9 Regional and Leading National Biopharmaceuticals Contract Manufacturing Market Forecasts 2022-2032

• 9.1 Global Biopharmaceuticals Contract Manufacturing Market by Region Forecast 2022-2032
• 9.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)

10 North America Biopharmaceuticals Contract Manufacturing Market

• 10.1 Regional Overview
• 10.2 North America Biopharmaceuticals Contract Manufacturing Market by Country, Forecast 2022-2032
• 10.3 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Source
• 10.4 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Service
• 10.5 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Product
• 10.6 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size
• 10.7 North America Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations
• 10.8 U.S. Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 10.8.1 Market Overview
  • 10.8.2 Global Leader in Biopharmaceutical Business
  • 10.8.3 U.S. Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 10.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): U.S. Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 10.9 Canada Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 10.9.1 Market Overview
  • 10.9.2 Collaborations Among Players to Fuel Canadian Biopharmaceutical Contract Manufacturing Market
  • 10.9.3 Canada Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 10.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Canada Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032

11 Europe Biopharmaceuticals Contract Manufacturing Market

• 11.1 Regional Overview
• 11.2 Europe Biopharmaceuticals Contract Manufacturing Market by Country, Forecast 2022-2032
• 11.3 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Source
• 11.4 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Service
• 11.5 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Product
• 11.6 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size
• 11.7 Europe Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations
• 11.8 Germany Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 11.8.1 Germany to Witness Highest Growth Rate Across European Region
  • 11.8.2 Market Overview
  • 11.8.3 COVID-19 Impact Analysis
  • 11.8.4 Germany Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 11.8.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): Germany Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 11.9 UK Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 11.9.1 Significant Biopharmaceutical Contribution
  • 11.9.2 Market Overview
  • 11.9.3 UK Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 11.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): UK Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 11.10 France Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 11.10.1 Robust Pipeline to Fuel Market Growth
  • 11.10.2 Growing Initiatives by Established Firms to Boost Market Growth
  • 11.10.3 France Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 11.10.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): France Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 11.11 Italy Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 11.11.1 Role of CDMO Business Across Italy
  • 11.11.2 Investment by Major Players to Fuel Market Expansion
  • 11.11.3 Italy Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 11.11.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Italy Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 11.12 Spain Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 11.12.1 Spain Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 11.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Spain Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 11.13 Rest of Europe Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 11.13.1 Rest of Europe Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 11.13.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Europe Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032

12 Asia Pacific Biopharmaceuticals Contract Manufacturing Market

• 12.1 Regional Overview
• 12.2 Asia Pacific Biopharmaceuticals Contract Manufacturing Market by Country, Forecast 2022-2032
• 12.3 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Source
• 12.4 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Service
• 12.5 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Product
• 12.6 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size
• 12.7 Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations
• 12.8 Japan Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 12.8.1 Bushu expects to double the volume of Amgen drugs it makes under new Asia CMO pact
  • 12.8.2 Japan Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 12.8.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Japan Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 12.9 China Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 12.9.1 Domestic Drug Innovation on Rise
  • 12.9.2 SK Biopharmaceuticals Enters Greater China Out-Licensing 6 Clinical Pipelines to CNS-Focused Biotech Ignis Therapeutics
  • 12.9.3 Strong Growth Provides CMO Opportunities
  • 12.9.4 China Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 12.9.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): China Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 12.10 India Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 12.10.1 The COVID-19 pandemic has brought India's biotechnology industry, especially biopharmaceuticals into the limelight
  • 12.10.2 Piramal Pharma Ltd. Invests Minority Stake in CDMO Yapan Bio
  • 12.10.3 India Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 12.10.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): India Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 12.11 Australia Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 12.11.1 BioCina Expands into Full-service mRNA CDMO
  • 12.11.2 Australia Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 12.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Australia Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 12.12 Southeast Asia Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 12.12.1 Southeast Asia Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 12.12.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Southeast Asia Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 12.13 Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 12.13.1 Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 12.13.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032

13 Latin America Biopharmaceuticals Contract Manufacturing Market

• 13.1 Regional Overview
• 13.2 Latin America Biopharmaceuticals Contract Manufacturing Market by Country, Forecast 2022-2032
• 13.3 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Source
• 13.4 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Service
• 13.5 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Product
• 13.6 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size
• 13.7 Latin America Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations
• 13.8 Brazil Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 13.8.1 Brazil Driving the Latin America Biopharmaceutical Contract Manufacturing Market
  • 13.8.2 Growing Pharmaceutical Sector to Fuel Market Growth
  • 13.8.3 Brazil Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 13.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Brazil Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 13.9 Mexico Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 13.9.1 Mexico is a Key Player in Biotechnology
  • 13.9.2 Mexico Targets a Group of Indian Generics Makers for Homeland Pharma Hub
  • 13.9.3 Mexico Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 13.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Mexico Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 13.10 Argentina Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 13.10.1 Argentina Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 13.10.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Argentina Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 13.11 Rest of Latin America Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 13.11.1 Rest of Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 13.11.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Latin America Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032

14 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market

• 14.1 Regional Overview
• 14.2 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market by Country, Forecast 2022-2032
• 14.3 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast by Source
• 14.4 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast by Service
• 14.5 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast by Product
• 14.6 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast by Company Size
• 14.7 Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast by Scale of Operations
• 14.8 GCC Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 14.8.1 Pharmaceutical Market Across GCC
  • 14.8.2 Growing Investment to Fuel Market Expansion
  • 14.8.3 Mubadala teams up with G42 to set up a biopharma manufacturing campus in Abu Dhabi
  • 14.8.4 GCC Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 14.8.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): GCC Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 14.9 South Africa Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 14.9.1 South African Evolving Demographic and Epidemiological Profile to Offer Lucrative Growth Prospects
  • 14.9.2 South Africa Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 14.9.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Africa Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
• 14.10 Rest of Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032
  • 14.10.1 Introduction
  • 14.10.2 Rest of Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Revenue, 2022-2032
  • 14.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Forecast, 2022-2032

15 Company Profiles

• 15.1 AbbVie, Inc.
  • 15.1.1 Company Snapshot
  • 15.1.2 Company Overview
  • 15.1.3 Financial Analysis
    • 15.1.3.1 Net Revenue, 2015-2020
    • 15.1.3.2 R&D Expenses, 2015-2020
    • 15.1.3.3 Gross Profit, 2015-2020
  • 15.1.4 Product Benchmarking
  • 15.1.5 Recent Developments till December 2021
• 15.2 AGC Biologics
  • 15.2.1 Company Snapshot
  • 15.2.2 Company Overview
  • 15.2.3 Product Benchmarking
  • 15.2.4 Recent Developments till December 2021
• 15.3 Avantor
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Financial Analysis
    • 15.3.3.1 Net Revenue, 2017-2020
    • 15.3.3.2 Gross Profit, 2017-2020
  • 15.3.4 Product Benchmarking
  • 15.3.5 Recent Developments till December 2021
• 15.4 Binex Co., Ltd.
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Product Benchmarking
• 15.5 Boehringer Ingelheim GmbH
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Financial Analysis
    • 15.5.3.1 Net Revenue, 2015-2020
  • 15.5.4 Product Benchmarking
  • 15.5.5 Recent Developments till December 2021
• 15.6 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Product Benchmarking
  • 15.6.4 Recent Developments till December 2021
• 15.7 Lonza
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Financial Analysis
    • 15.7.3.1 Net Revenue, 2015-2020
    • 15.7.3.2 R&D Expenses, 2017-2020
    • 15.7.3.3 Gross Profit, 2015-2020
  • 15.7.4 Product Benchmarking
  • 15.7.5 Recent Developments till December 2021
• 15.8 ProBioGen
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Product Benchmarking
  • 15.8.4 Recent Developments till January 2022
• 15.9 Rentschler Biopharma SE
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Product Benchmarking
  • 15.9.4 Recent Developments till December 2021
• 15.10 Samsung BioLogics
  • 15.10.1 Company Snapshot
  • 15.10.2 Company Overview
  • 15.10.3 Product Benchmarking
  • 15.10.4 Recent Developments till December 2021
• 15.11 Sandoz
  • 15.11.1 Company Snapshot
  • 15.11.2 Company Overview
  • 15.11.3 Financial Analysis
    • 15.11.3.1 Net Revenue, 2015-2020
  • 15.11.4 Product Benchmarking
  • 15.11.5 Recent Developments till December 2021
• 15.12 TOYOBO CO., LTD.
  • 15.12.1 Company Snapshot
  • 15.12.2 Company Overview
  • 15.12.3 Product Benchmarking
• 15.13 WuXi Biologics
  • 15.13.1 Company Snapshot
  • 15.13.2 Company Overview
  • 15.13.3 Financial Analysis
    • 15.13.3.1 Net Revenue, 2015-2020
    • 15.13.3.2 Gross Profit, 2015-2020
  • 15.13.4 Product Benchmarking
  • 15.13.5 Recent Developments till January 2022
• 15.14 JRS PHARMA
  • 15.14.1 Company Snapshot
  • 15.14.2 Company Overview
  • 15.14.3 Product Benchmarking
  • 15.14.4 Recent Developments till January 2022
• 15.15 Thermo Fisher Scientific
  • 15.15.1 Company Snapshot
  • 15.15.2 Company Overview
  • 15.15.3 Financial Analysis
    • 15.15.3.1 Net Revenue, 2015-2020
    • 15.15.3.2 R&D, 2015-2020
    • 15.15.3.3 Gross Profit, 2015-2020
  • 15.15.4 Product Benchmarking
• 15.16 Cambrex Corporation
  • 15.16.1 Company Snapshot
  • 15.16.2 Company Overview
  • 15.16.3 Product Benchmarking
  • 15.16.4 Recent Developments till January 2022
• 15.17 Curia Global, Inc.
  • 15.17.1 Company Snapshot
  • 15.17.2 Company Overview
  • 15.17.3 Product Benchmarking
  • 15.17.4 Recent Developments till January 2022
• 15.18 Pfizer CentreOne
  • 15.18.1 Company Snapshot
  • 15.18.2 Company Overview
  • 15.18.3 Financial Analysis
    • 15.18.3.1 Net Revenue, 2015-2020
    • 15.18.3.2 R&D, 2015-2020
    • 15.18.3.3 Gross Profit, 2015-2020
  • 15.18.4 Product Benchmarking
• 15.19 Jubilant Pharma Limited
  • 15.19.1 Company Snapshot
  • 15.19.2 Company Overview
  • 15.19.3 Product Benchmarking

16 Conclusion and Recommendations

• 16.1 Concluding Remarks
• 16.2 Recommendations
• 16.3 Leading Biopharmaceuticals Contract Manufacturing Market by Region

관련자료